drugset / Trial / NCT00979654
A Study to Evaluate the Long-Term Safety of MEDI-545 in Adult Participants With Systemic Lupus Erythematosus or Myositis
NaSingle-groupOpen-labelTreatment
Summary
The objective of this study is to assess the safety and tolerability of sifalimumab in adult participants with active systemic lupus erythematosus (SLE) or active dermatomyositis (DM) or polymyositis (PM) who participated in the following clinical studies: MI-CP151, MI-CP152, or MI-CP179.
Timeline
- Start
- 2010-08
- Primary completion
- 2015-03
- Completion
- 2015-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Sifalimumab | Monoclonal antibody | 500 mg | Intravenous |
| Subject | Sifalimumab | Monoclonal antibody | 600 mg | Intravenous |